Skip to main content
Premium Trial:

Request an Annual Quote

Roche Amends ProbeLibrary Licensing Deal with Exiqon

NEW YORK (GenomeWeb News) – Roche Diagnostics and Danish firm Exiqon have amended their 2005 licensing agreement covering the Universal ProbeLibrary, which is based on Exiqon’s Locked Nucleic Acid oligonucleotides.
Roche said that its exclusive rights to sell and distribute the ProbeLibrary products have been extended on a co-exclusive basis. It also gained co-exclusive rights to use the ProbeLibrary in developing and manufacturing its new line of RealTime ready qPCR assays, which are gene expression assays that can run in a single assay format or in a multiwell plate format on its LightCycler System.
The partners did not disclose the length of the new contract or provide financial terms of the amended pact.
“We will address the need for increased speed and flexibility in biomedical research providing customized on demand supply of single assays and ready to use qPCR panels for virtually every gene of the human genome and other important organisms,” Manfried Baier, head of Roche Applied Science, a business area within Roche Diagnostics, said in a statement.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.